Saddik M, el Dabbagh L, Mourad W A
Department of Pathology, King Faisal Specialist Hospital, Riyadh, Saudi Arabia.
Diagn Cytopathol. 1997 Feb;16(2):126-31. doi: 10.1002/(sici)1097-0339(199702)16:2<126::aid-dc6>3.0.co;2-f.
Surface marker characterization of lymphoproliferative disorders is an essential component in the diagnostic work-up of these lesions. Immunohistochemical surface marker analysis (SMA) is somewhat costly, fixation-dependent, and difficult to objectively quantitate. Two-color flow cytometric (TCFCM) SMA allows for more quantitative dual marker analysis of a wide range of surface antigens, and is less expensive. Ex vivo fine-needle aspiration (xvFNA) has been reliably used for FCM DNA analysis. The procedure has also been used to harvest tumor cells for xenotransplantation. In this study, we attempted to test the reliability of material obtained by xvFNA for SMA. We also designed an algorithm initiated by cytological assessment of the xvFNA smears in order to tailor the panel of antibodies required for TCFCM SMA of the aspirates. We performed 20 xvFNAs on freshly resected specimens from 19 patients with suspected lymphoproliferative disorders. The specimens included 12 lymph node biopsies, seven splenectomies, and one breast biopsy. There were 10 male and nine female patients with a median age of 58 yr. The aspirate cell suspensions were examined by FCM within 24 hr of harvesting. The number of markers used ranged from four to 14 with an average of eight. The diagnoses included non-Hodgkin's lymphoma (n = 5), lymphocytic leukemia (n = 5), reactive lymphoid hyperplasia (n = 8), and Hodgkin's disease (n = 1). Combining cytological assessment of the xvFNA smears and TCFCM SMA, the diagnosis was reached prior to histopathologic examination in 17 cases (90%). The two remaining cases showed a reactive pattern on cytology and a polyclonal FCM SMA profile, and the diagnosis of sarcoidosis and toxoplasmosis was made on histological examination. Our study suggests that xvFNA provides adequate material for TCFCM SMA. An algorithm combining xvFNA cytology, FCM SMA, and histological examination is appropriate for the diagnosis of lymphoproliferative disorders in most instances with maximal resource utilization and minimal expense.
淋巴细胞增生性疾病的表面标志物特征是这些病变诊断检查的重要组成部分。免疫组织化学表面标志物分析(SMA)成本较高、依赖固定且难以客观定量。双色流式细胞术(TCFCM)SMA能够对多种表面抗原进行更定量的双标志物分析,且成本较低。体外细针穿刺抽吸(xvFNA)已可靠地用于FCM DNA分析。该方法也已用于采集肿瘤细胞进行异种移植。在本研究中,我们试图测试通过xvFNA获得的材料用于SMA的可靠性。我们还设计了一种算法,该算法由对xvFNA涂片的细胞学评估启动,以便定制抽吸物TCFCM SMA所需的抗体组合。我们对19例疑似淋巴细胞增生性疾病患者的新鲜切除标本进行了20次xvFNA。标本包括12例淋巴结活检、7例脾切除术和1例乳房活检。有10例男性和9例女性患者,中位年龄为58岁。抽吸细胞悬液在采集后24小时内通过FCM进行检查。使用的标志物数量从4个到14个不等,平均为8个。诊断包括非霍奇金淋巴瘤(n = 5)、淋巴细胞白血病(n = 5)、反应性淋巴组织增生(n = 8)和霍奇金病(n = 1)。结合xvFNA涂片的细胞学评估和TCFCM SMA,17例(90%)在组织病理学检查之前就得出了诊断。其余2例在细胞学上表现为反应性模式,FCM SMA呈多克隆图谱,组织学检查诊断为结节病和弓形虫病。我们的研究表明,xvFNA为TCFCM SMA提供了足够的材料。结合xvFNA细胞学、FCM SMA和组织学检查的算法在大多数情况下适用于淋巴细胞增生性疾病的诊断,能最大程度地利用资源并降低费用。